Questões Militares Para ime
Foram encontradas 960 questões
Resolva questões gratuitamente!
Junte-se a mais de 4 milhões de concurseiros!
Texto 3
THE DISCOVERY OF PENICILLIN—NEW INSIGHTS AFTER MORE THAN 75 YEARS OF CLINICAL USE
ABSTRACT
After just over 75 years of penicillin’s clinical use, the world can see that its impact was immediate and profound. In 1928, a chance event in Alexander Fleming’s London laboratory changed the course of medicine. However, the purification and first clinical use of penicillin would take more than a decade. Unprecedented United States/Great Britain cooperation to produce penicillin was incredibly successful by 1943. This success overshadowed efforts to produce penicillin during World War II in Europe, particularly in the Netherlands. Information about these efforts, available only in the last 10–15 years, provides new insights into the story of the first antibiotic. Researchers in the Netherlands produced penicillin using their own production methods and marketed it in 1946, which eventually increased the penicillin supply and decreased the price. The unusual serendipity involved in the discovery of penicillin demonstrates the difficulties in finding new antibiotics and should remind health professionals to expertly manage these extraordinary medicines.
( . . . )
GAYNES, R. The Discovery of Penicillin—New Insights After More Than 75 Years of Clinical Use. In: Science, 2017. Disponível em: <http://wwwnc.cdc.gov/eid/article/23/5/16-1556_article>. Acesso em: 26/06/2018.
Choose the correct option.
The meaning of the word “serendipity” in the sentence: “The unusual serendipity involved in the discovery of penicillin demonstrates the difficulties in finding new antibiotics (...)” is:
Texto 3
THE DISCOVERY OF PENICILLIN—NEW INSIGHTS AFTER MORE THAN 75 YEARS OF CLINICAL USE
ABSTRACT
After just over 75 years of penicillin’s clinical use, the world can see that its impact was immediate and profound. In 1928, a chance event in Alexander Fleming’s London laboratory changed the course of medicine. However, the purification and first clinical use of penicillin would take more than a decade. Unprecedented United States/Great Britain cooperation to produce penicillin was incredibly successful by 1943. This success overshadowed efforts to produce penicillin during World War II in Europe, particularly in the Netherlands. Information about these efforts, available only in the last 10–15 years, provides new insights into the story of the first antibiotic. Researchers in the Netherlands produced penicillin using their own production methods and marketed it in 1946, which eventually increased the penicillin supply and decreased the price. The unusual serendipity involved in the discovery of penicillin demonstrates the difficulties in finding new antibiotics and should remind health professionals to expertly manage these extraordinary medicines.
( . . . )
GAYNES, R. The Discovery of Penicillin—New Insights After More Than 75 Years of Clinical Use. In: Science, 2017. Disponível em: <http://wwwnc.cdc.gov/eid/article/23/5/16-1556_article>. Acesso em: 26/06/2018.
Texto 2
CORPORATE CONTROL AND GLOBAL GOVERNANCE OF MARINE GENETIC RESOURCES
INTRODUCTION
The prospect of the ocean generating a new era of “blue growth” is increasingly finding its way into national and international policy documents around the world and has spurred a rush to claim ocean space and resources. If economic activities in coastal and offshore areas are to expand in an equitable and sustainable manner, in line with the Sustainable Development Goals (SDGs), progress is needed toward addressing multiple and potentially conflicting uses of ocean space within national jurisdictions, in addition to developing a consistent and transparent legal framework for the vast areas beyond national jurisdiction (ABNJ). These areas cover 64% of the world’s ocean and 47% of the Earth’s surface yet remain poorly understood or described.
Marine organisms have evolved to thrive in the extremes of pressure, temperature, chemistry, and darkness found in the ocean, resulting in unique adaptations that make them the object of commercial interest, particularly for biomedical and industrial applications. By 2025, the global market for marine biotechnology is projected to reach $6.4 billion, spanning a broad range of commercial purposes for the pharmaceutical, biofuel, and chemical industries. One way to ensure exclusive access to these potential economic benefits is through patents associated with “marine genetic resources” (MGRs). Although the term MGRs has never been formally described, it suggests a subset of “genetic resources”, which have been defined under the Convention on Biological Diversity (CBD) as “genetic material of actual or potential value”._(33)_. The adoption of the Nagoya Protocol in 2010 represented an important step within the international policy arena to define obligations associated with monetary and nonmonetary benefit sharing of genetic resources and their products sourced from within national jurisdictions. No such mechanism currently exists for ABNJ.
( . . . )
BLASIAK, R.; JOUFFRAY, JB.; WABNITZ, C.; SUNDSTROM, E. e OSTERBLOM, H. Adaptado de Corporate control and global governance of marine genetic resources. In: Science Advances. Disponível em <http://advances.sciencemag.org/ content/4/6/eaar5237.full>. Acesso em: 07/08/2018.
Texto 2
CORPORATE CONTROL AND GLOBAL GOVERNANCE OF MARINE GENETIC RESOURCES
INTRODUCTION
The prospect of the ocean generating a new era of “blue growth” is increasingly finding its way into national and international policy documents around the world and has spurred a rush to claim ocean space and resources. If economic activities in coastal and offshore areas are to expand in an equitable and sustainable manner, in line with the Sustainable Development Goals (SDGs), progress is needed toward addressing multiple and potentially conflicting uses of ocean space within national jurisdictions, in addition to developing a consistent and transparent legal framework for the vast areas beyond national jurisdiction (ABNJ). These areas cover 64% of the world’s ocean and 47% of the Earth’s surface yet remain poorly understood or described.
Marine organisms have evolved to thrive in the extremes of pressure, temperature, chemistry, and darkness found in the ocean, resulting in unique adaptations that make them the object of commercial interest, particularly for biomedical and industrial applications. By 2025, the global market for marine biotechnology is projected to reach $6.4 billion, spanning a broad range of commercial purposes for the pharmaceutical, biofuel, and chemical industries. One way to ensure exclusive access to these potential economic benefits is through patents associated with “marine genetic resources” (MGRs). Although the term MGRs has never been formally described, it suggests a subset of “genetic resources”, which have been defined under the Convention on Biological Diversity (CBD) as “genetic material of actual or potential value”._(33)_. The adoption of the Nagoya Protocol in 2010 represented an important step within the international policy arena to define obligations associated with monetary and nonmonetary benefit sharing of genetic resources and their products sourced from within national jurisdictions. No such mechanism currently exists for ABNJ.
( . . . )
BLASIAK, R.; JOUFFRAY, JB.; WABNITZ, C.; SUNDSTROM, E. e OSTERBLOM, H. Adaptado de Corporate control and global governance of marine genetic resources. In: Science Advances. Disponível em <http://advances.sciencemag.org/ content/4/6/eaar5237.full>. Acesso em: 07/08/2018.
Texto 2
CORPORATE CONTROL AND GLOBAL GOVERNANCE OF MARINE GENETIC RESOURCES
INTRODUCTION
The prospect of the ocean generating a new era of “blue growth” is increasingly finding its way into national and international policy documents around the world and has spurred a rush to claim ocean space and resources. If economic activities in coastal and offshore areas are to expand in an equitable and sustainable manner, in line with the Sustainable Development Goals (SDGs), progress is needed toward addressing multiple and potentially conflicting uses of ocean space within national jurisdictions, in addition to developing a consistent and transparent legal framework for the vast areas beyond national jurisdiction (ABNJ). These areas cover 64% of the world’s ocean and 47% of the Earth’s surface yet remain poorly understood or described.
Marine organisms have evolved to thrive in the extremes of pressure, temperature, chemistry, and darkness found in the ocean, resulting in unique adaptations that make them the object of commercial interest, particularly for biomedical and industrial applications. By 2025, the global market for marine biotechnology is projected to reach $6.4 billion, spanning a broad range of commercial purposes for the pharmaceutical, biofuel, and chemical industries. One way to ensure exclusive access to these potential economic benefits is through patents associated with “marine genetic resources” (MGRs). Although the term MGRs has never been formally described, it suggests a subset of “genetic resources”, which have been defined under the Convention on Biological Diversity (CBD) as “genetic material of actual or potential value”._(33)_. The adoption of the Nagoya Protocol in 2010 represented an important step within the international policy arena to define obligations associated with monetary and nonmonetary benefit sharing of genetic resources and their products sourced from within national jurisdictions. No such mechanism currently exists for ABNJ.
( . . . )
BLASIAK, R.; JOUFFRAY, JB.; WABNITZ, C.; SUNDSTROM, E. e OSTERBLOM, H. Adaptado de Corporate control and global governance of marine genetic resources. In: Science Advances. Disponível em <http://advances.sciencemag.org/ content/4/6/eaar5237.full>. Acesso em: 07/08/2018.